Log In
BCIQ
Print this Print this
 

solifenacin/mirabegron (EB178)

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionCombination of solifenacin and mirabegron
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationIncontinence
Indication DetailsTreat overactive bladder (OAB)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today